Nancy E Sealover
6PUBLICATIONS
50CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Sep 16, 2025
Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers.Nancy E Sealover, Bridget A Finniff, Jacob M Hughes
|Oct 22, 2024
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.Brianna R Daley, Nancy E Sealover, Bridget A Finniff
|Nov 02, 2022
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.Katie E Hebron, Xiaolin Wan, Jacob S Roth
|Aug 09, 2022
Heterogeneity in RAS mutations: One size does not fit all.Nancy E Sealover, Robert L Kortum
|May 08, 2019
Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells.Erin Sheffels, Nancy E Sealover, Patricia L Theard
|Sep 06, 2018
Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.Erin Sheffels, Nancy E Sealover, Chenyue Wang
Pageof 1
Frequent Collaborators
5 joint publications
Robert L Kortum
4 joint publications
Erin Sheffels
2 joint publications
Amanda Linke
2 joint publications
Joseph P LaMorte
2 joint publications
Matthew D Wilkerson
2 joint publications
Jacob M Hughes
2 joint publications
Marielle E Yohe
1 joint publications
Do Hyung Kim
1 joint publications
Katie E Hebron
1 joint publications
Xiaolin Wan
